依达拉奉在神经外科疾病中的临床疗效观察

Observation Clinical Curative Effect of Edaravone in Neurosurgery Diseases

目的 探讨依达拉奉在神经外科疾病中的临床疗效和安全性.方法 选择于2013年6月～2014年6月我院收治的神经外科患者72例作为研究对象,随机分为观察组和对照组,每组36例.对照组采用常规治疗方式,观察组在常规治疗基础上,使用30 mg依达拉奉,2次/d,连续治疗14 d.观察对比两组患者的临床疗效,ESS和ADL评分以及不良反应的发生情况.结果 观察组的临床总有效率为72.2%,优于对照组的50%,P＜0.05,差异具有统计学意义.治疗前,两组患者的ESS评分和ADL评分无显著性差异.治疗后观察组的ESS评分和ADL评分都优于对照组,P＜0.05,差异具有统计学意义,两组患者的不良反应无显著性差异.结论 依达拉奉治疗神经外科疾病安全有效.

Objective To observe and discuss the clinical efficacy and safety of edaravone for the treatment of neurosurgery related diseases. Methods Selected 72 patients who were treated for neurosurgery related diseases from June 2013 to June 2014 in our hospital as the research subjects, were randomly divided into the observation group and the control group, each group had 36 cases. The control group was treated with routine method, while the observation group was using edaravone 30 mg, 2 times each day, continuous treatment for 14 days based on routine treatment. The clinical efficacy, ADL, ESS scores and adverse reactions of the two groups were observed and compared.Results The clinical total effective rate of the observation group was 72.2%, it was better than the control group 50%, P〈0.05, was difference had statistically significance. Before treatment, there were no significant differences for ESS and ADL scores between the two groups. After treatment, the ESS score and ADL score of the observation group were better than the control group,P〈0.05, was difference had statistically significance. There were no significant differences in adverse reactions between the two groups.Conclusion Edaravone is effective and safety for the treatment of neurosurgery related diseases.